Test Catalog

Test ID: LIPA1    
Lipoprotein(a), Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

Cardiovascular disease (CVD) risk refinement in patients with moderate or high risk based on conventional risk factors or patients with clinical suspicion of residual CV risk not identified by other lipid parameters

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Lipoprotein (a) consists of a low-density lipoprotein (LDL) particle that is covalently bound to an additional protein, apolipoprotein (a) [Apo(a)]. Apo(a) has high sequence homology with the coagulation factor plasminogen, and like LDL, Lp(a) contains apolipoprotein B100 (ApoB). Thus, Lp(a) is both proatherogenic and prothrombotic.


Lp(a) is an independent risk factor for coronary heart disease (CHD), ischemic stroke, and aortic valve stenosis. Lp(a) has been referred to as "the most atherogenic lipoprotein". The mechanism of increased risk is unclear but most likely involves progression of atherosclerotic stenosis via intimal deposition of cholesterol and promotion of thrombosis via homology to plasminogen.


Accurate immunochemical measurement of Lp(a) is complicated by the heterogeneity of Lp(a) molecular size. Due to the large number of polymorphisms (varying number of kringle domain repeats in the Apo[a] protein) in the population, any given individual can have an Apo(a) protein between 240 to 800 kDa. This heterogeneity leads to inaccuracies in all immunoassay. In addition, the degree of atherogenicity of the Lp(a) particle may depend on the molecular size of the Lp(a)-specific protein. However, the measurement of Lp(a) using immunoassays calibrated to molar units is recommended to minimize assay inaccuracies caused by Apo(a) isoform size.


Serum concentrations of Lp(a) are related to genetic factors, specifically the expression of Apo(a), and are largely unaffected by diet, exercise, and lipid-lowering pharmaceuticals. However, in a patient with additional modifiable CHD risk factors, more aggressive therapy to normalize these factors may be indicated if the Lp(a) value is also increased. In cases of extremely elevated Lp(a), lipoprotein apheresis may be considered.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

> or =18 years: <75 nmol/L

Values > or =75 nmol/L may suggest increased risk of coronary heart disease.

Values > or =175 nmol/L is considered a risk-enhancing factor for cardiovascular disease by several professional societies. Clinician-patient discussion of therapeutic strategy is warranted.


Reference values have not been established for patients who are less than 18 years of age.

Interpretation Provides information to assist in interpretation of the test results

Lipoprotein (a) (Lp[a]) concentrations of 75 nmol/L and above is linearly related to increased risk of cardiovascular events independent of conventional risk markers.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Epidemiologic studies have shown lipoprotein (a) (Lp[a]) concentrations are lowest in non-Hispanic white, Chinese, and Japanese populations. The Hispanic population has a slightly higher median Lp(a) concentration, and, in the African American population, the median Lp(a) serum concentration is approximately 2 times higher than in the white population.


In very rare cases, gammopathy, type IgM (Waldenstrom macroglobulinemia) in particular, may cause unreliable results.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009 Jul 22;302(4):412-423

2. Tsimikas S: A test in context: Lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042

3. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S: Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clin Chem. 2003 Nov;49(11):1785-1796

4. Wilson DP, Jacobson TA, Jones PH, et al: Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019 May-Jun;13(3):374-392. doi: 10.1016/j.jacl.2019.04.010